Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Novartis. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$761.47 +21.40 (+2.89%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$761.75 +0.28 (+0.04%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $761, reflecting strong market interest and potential for growth.
  • Seventeen analysts have issued a buy rating, indicating strong confidence in the company's future performance.
  • The company reported a significant year-over-year revenue increase of over 45%, showcasing robust business growth.

Cons of Eli Lilly and Company

  • The company recently missed earnings expectations, reporting $3.34 EPS compared to the consensus estimate of $4.64, which may raise concerns about future profitability.
  • One analyst has rated the stock with a sell rating, indicating potential risks that could affect stock performance.
  • HSBC downgraded the stock from a buy to a reduce rating, reflecting a more cautious outlook from some market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$721.68 billion
P/E Ratio
61.96
Consensus Rating
Moderate Buy
Consensus Price Target
$1,012.56 (+33.0% Upside)
Volume
4.86 million shares
Average Volume
3.53 million shares
Today's Range
$745.99
$768.00
50-Day Range
$713.99
$818.56
52-Week Range
$677.09
$972.53
Dividend Yield
0.79%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$167.33 +2.59 (+1.57%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$167.30 -0.03 (-0.01%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $167, reflecting a stable performance in the market.
  • Johnson & Johnson recently reported earnings per share (EPS) of $2.77, exceeding analyst expectations, which indicates strong financial health and operational efficiency.
  • The company has a solid revenue growth of 5.8% year-over-year, showcasing its ability to expand and adapt in a competitive market.

Cons of Johnson & Johnson

  • Despite recent earnings growth, the company reported a slight decline in EPS compared to the previous year, which may raise concerns about future profitability.
  • Johnson & Johnson has a relatively high price-to-earnings (P/E) ratio of 17.90, which could suggest that the stock is overvalued compared to its earnings potential.
  • The company has a debt-to-equity ratio of 0.50, indicating a moderate level of debt that could impact financial flexibility in challenging economic conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$402.99 billion
P/E Ratio
17.90
Consensus Rating
Moderate Buy
Consensus Price Target
$174.50 (+4.3% Upside)
Volume
8.91 million shares
Average Volume
8.83 million shares
Today's Range
$164.79
$167.62
50-Day Range
$149.81
$169.62
52-Week Range
$140.68
$169.99
Dividend Yield
3.11%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$195.17 +6.15 (+3.25%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$195.10 -0.07 (-0.04%)
As of 08/1/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $195, reflecting a strong market presence and investor interest.
  • AbbVie reported a revenue increase of 6.6% year-over-year, indicating robust growth in its business operations.
  • The company has a high return on equity, showcasing its efficiency in generating profits from shareholders' equity.

Cons of AbbVie

  • The stock has a high price-to-earnings ratio, which may indicate that it is overvalued compared to its earnings potential.
  • AbbVie recently missed earnings estimates, which could raise concerns about its ability to meet future financial expectations.
  • The company has a significant debt-to-equity ratio, suggesting a reliance on debt financing that could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$344.75 billion
P/E Ratio
92.94
Consensus Rating
Moderate Buy
Consensus Price Target
$212.81 (+9.0% Upside)
Volume
8.08 million shares
Average Volume
5.84 million shares
Today's Range
$189.79
$197.06
50-Day Range
$181.89
$195.17
52-Week Range
$163.81
$218.66
Dividend Yield
3.36%
Novartis stock logo

4. Novartis NYSE:NVS

$115.25 +1.51 (+1.33%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$113.93 -1.32 (-1.15%)
As of 08/1/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG recently reported earnings per share of $2.42, exceeding analyst expectations, which indicates strong financial performance and potential for future growth.
  • The company has demonstrated a significant year-over-year revenue increase of 12.3%, suggesting robust demand for its healthcare products.
  • With a return on equity of over 41%, Novartis AG shows effective management and profitability, which can be attractive to investors looking for efficient capital use.

Cons of Novartis

  • Despite strong earnings, the stock has seen fluctuations, with recent trading down about 3% in a single day, indicating potential volatility.
  • Analyst ratings show a mix of opinions, with several analysts maintaining a "hold" rating, suggesting uncertainty about the stock's short-term performance.
  • The company's debt-to-equity ratio of 0.53, while manageable, indicates some level of leverage that could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$243.46 billion
P/E Ratio
16.78
Consensus Rating
Hold
Consensus Price Target
$123.67 (+7.3% Upside)
Volume
1.93 million shares
Average Volume
2.06 million shares
Today's Range
$112.34
$115.54
50-Day Range
$111.88
$123.83
52-Week Range
$96.06
$124.83
Dividend Yield
2.25%
AstraZeneca stock logo

5. AstraZeneca NASDAQ:AZN

$73.95 +0.86 (+1.18%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$73.50 -0.45 (-0.61%)
As of 08/1/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $73.98, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • AstraZeneca reported a significant year-over-year revenue increase of 16.1%, indicating strong business performance and potential for future growth.
  • The company has a solid return on equity of 33.14%, suggesting effective management and profitability, which can be attractive to investors.

Cons of AstraZeneca

  • The company has a debt-to-equity ratio of 0.65, which, while manageable, indicates that it relies on debt financing, potentially increasing financial risk.
  • AstraZeneca's current ratio of 0.90 suggests that it may face challenges in meeting short-term liabilities, which could be a concern for investors focused on liquidity.
  • The stock has experienced fluctuations, with a 52-week low of $61.24, indicating volatility that may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$229.34 billion
P/E Ratio
27.80
Consensus Rating
Moderate Buy
Consensus Price Target
$89.00 (+20.4% Upside)
Volume
9.73 million shares
Average Volume
5.49 million shares
Today's Range
$73.34
$74.12
50-Day Range
$68.72
$76.59
52-Week Range
$61.24
$87.68
Dividend Yield
2.79%
Abbott Laboratories stock logo

6. Abbott Laboratories NYSE:ABT

$127.32 +1.13 (+0.90%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$127.35 +0.03 (+0.02%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The company recently reported strong quarterly earnings, with earnings per share (EPS) meeting analysts' expectations, indicating stable financial performance.
  • Abbott Laboratories has shown a year-over-year revenue increase, reflecting growth in its business operations and market demand for its healthcare products.
  • The current stock price is around $144, which is considered attractive given the company's solid fundamentals and growth prospects.

Cons of Abbott Laboratories

  • Despite strong earnings, the stock has faced fluctuations, which may indicate volatility and potential risks for investors.
  • Some analysts have set target prices that suggest limited upside potential, which could affect future returns on investment.
  • The healthcare sector can be highly competitive and subject to regulatory changes, which may impact Abbott Laboratories' market position.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$221.60 billion
P/E Ratio
15.95
Consensus Rating
Moderate Buy
Consensus Price Target
$144.47 (+13.5% Upside)
Volume
5.45 million shares
Average Volume
7.98 million shares
Today's Range
$125.47
$127.77
50-Day Range
$120.76
$138.13
52-Week Range
$107.11
$141.23
Dividend Yield
1.85%
UnitedHealth Group stock logo

7. UnitedHealth Group NYSE:UNH

$237.40 -12.16 (-4.87%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$237.23 -0.17 (-0.07%)
As of 08/1/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $373.52, which reflects a consensus rating of "Hold" from analysts, indicating potential stability in the stock's performance.
  • UnitedHealth Group has received multiple "buy" ratings from analysts, suggesting strong confidence in the company's growth prospects and market position.
  • Recent insider buying activity, including a significant purchase by the CFO, indicates that company leadership is optimistic about the future performance of the stock.

Cons of UnitedHealth Group

  • Some analysts have downgraded their ratings, with a few moving from "buy" to "hold," which may indicate concerns about the company's short-term performance.
  • There are several "sell" ratings from analysts, suggesting that a portion of the market may have reservations about the company's future growth.
  • Recent price target reductions by analysts could signal a lack of confidence in the stock's ability to maintain its previous highs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$215.36 billion
P/E Ratio
10.29
Consensus Rating
Moderate Buy
Consensus Price Target
$373.52 (+57.3% Upside)
Volume
39.87 million shares
Average Volume
17.27 million shares
Today's Range
$234.60
$251.49
50-Day Range
$237.40
$325.83
52-Week Range
$234.60
$630.73
Dividend Yield
3.72%
Novo Nordisk A/S stock logo

8. Novo Nordisk A/S NYSE:NVO

$48.23 +1.16 (+2.46%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$48.36 +0.13 (+0.27%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $47, which may present a buying opportunity for investors looking for value in the biotech sector.
  • Recent upgrades and downgrades from various analysts indicate a mix of confidence in the company's future performance, with some analysts maintaining a "buy" rating.
  • With a market capitalization of approximately $209.94 billion, Novo Nordisk is a significant player in the pharmaceutical industry, suggesting stability and potential for growth.

Cons of Novo Nordisk A/S

  • Recent downgrades from analysts, including a shift from "strong-buy" to "hold," may signal concerns about the company's growth prospects.
  • The stock has experienced a decline of about 6% recently, which could indicate volatility and potential risks for investors.
  • Analysts have set a lower price target for the stock, which may suggest that the market is adjusting its expectations for future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$215.35 billion
P/E Ratio
14.27
Consensus Rating
Hold
Consensus Price Target
$93.67 (+94.2% Upside)
Volume
34.71 million shares
Average Volume
19.35 million shares
Today's Range
$47.55
$49.03
50-Day Range
$47.02
$81.07
52-Week Range
$46.90
$139.74
Dividend Yield
3.40%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$79.27 +1.15 (+1.47%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$79.28 +0.02 (+0.02%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $80, which may present a buying opportunity for investors looking for value.
  • Merck has a strong market capitalization of approximately $199 billion, indicating a solid position in the pharmaceutical industry.
  • The company reported earnings per share (EPS) of $2.13, exceeding analyst expectations, which reflects strong financial performance.

Cons of Merck & Co., Inc.

  • Recent price target reductions by analysts, including a drop to $90 from $97, may indicate a lack of confidence in short-term growth.
  • Merck's revenue for the last quarter was slightly below analyst estimates, which could raise concerns about future performance.
  • The company has a debt-to-equity ratio of 0.69, which, while manageable, indicates some level of financial leverage that could pose risks.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$199.05 billion
P/E Ratio
12.21
Consensus Rating
Hold
Consensus Price Target
$107.44 (+35.5% Upside)
Volume
11.90 million shares
Average Volume
13.11 million shares
Today's Range
$77.53
$79.87
50-Day Range
$76.17
$84.82
52-Week Range
$73.31
$120.30
Dividend Yield
4.09%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$462.74 -4.94 (-1.06%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$464.00 +1.26 (+0.27%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The company recently reported strong quarterly earnings, with earnings per share (EPS) exceeding analyst expectations, indicating robust financial health and operational efficiency.
  • Thermo Fisher Scientific Inc. has shown a consistent revenue growth of approximately 2.9% compared to the same quarter last year, reflecting its ability to expand its market presence.
  • The current stock price is around $590, which is significantly below its 52-week high of $627.88, suggesting potential for price appreciation as the market stabilizes.

Cons of Thermo Fisher Scientific

  • The stock has experienced fluctuations, with analysts providing a wide range of target prices, indicating uncertainty in future performance.
  • Recent analyst downgrades, including a reduction in target prices by some firms, may signal a lack of confidence in the stock's near-term prospects.
  • Despite a positive earnings report, the EPS of $5.36 is slightly lower than the previous year's $5.37, which could raise concerns about growth sustainability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$174.68 billion
P/E Ratio
26.76
Consensus Rating
Moderate Buy
Consensus Price Target
$593.00 (+28.1% Upside)
Volume
2.76 million shares
Average Volume
3.36 million shares
Today's Range
$451.45
$464.10
50-Day Range
$390.17
$484.90
52-Week Range
$385.46
$627.88
Dividend Yield
0.37%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$483.12 +2.03 (+0.42%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$484.75 +1.63 (+0.34%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $496.87, which may present a buying opportunity for investors looking to enter at a lower price point.
  • Intuitive Surgical, Inc. reported strong earnings recently, with earnings per share exceeding expectations, indicating robust financial health and operational efficiency.
  • The company has a significant market capitalization of approximately $178.12 billion, suggesting stability and a strong position in the medical equipment sector.

Cons of Intuitive Surgical

  • The stock has experienced fluctuations, with a twelve-month high of $616.00 and a low of $425.00, indicating potential volatility that could concern risk-averse investors.
  • Despite recent earnings growth, the company has a high price-to-earnings (P/E) ratio of 69.30, which may suggest that the stock is overvalued compared to its earnings.
  • Recent insider sales, including a significant transaction by a senior vice president, could raise concerns about the executives' confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$173.19 billion
P/E Ratio
67.38
Consensus Rating
Moderate Buy
Consensus Price Target
$595.95 (+23.4% Upside)
Volume
2.98 million shares
Average Volume
2.15 million shares
Today's Range
$473.24
$486.06
50-Day Range
$481.09
$558.06
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$296.88 +1.78 (+0.60%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$297.50 +0.62 (+0.21%)
As of 08/1/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. recently reported earnings per share of $4.90, significantly exceeding the consensus estimate, indicating strong financial performance and effective management.
  • The company's revenue for the latest quarter was $8.15 billion, surpassing expectations, which reflects robust demand for its products and potential for future growth.
  • Amgen Inc. has a solid market capitalization of approximately $158.68 billion, suggesting it is a well-established player in the biotechnology sector.

Cons of Amgen

  • Despite recent earnings growth, the company's price-to-earnings ratio of 26.93 may suggest that the stock is overvalued compared to its earnings potential.
  • Amgen Inc. has a high debt-to-equity ratio of 8.70, which could indicate financial risk, as the company relies heavily on debt to finance its operations.
  • Recent insider selling, including a senior vice president selling 1,500 shares, may raise concerns about the company's future performance and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$159.64 billion
P/E Ratio
27.09
Consensus Rating
Hold
Consensus Price Target
$307.27 (+3.5% Upside)
Volume
2.41 million shares
Average Volume
1.83 million shares
Today's Range
$292.59
$298.52
50-Day Range
$271.66
$309.22
52-Week Range
$253.30
$339.17
Dividend Yield
3.21%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$105.40 +0.48 (+0.46%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$105.59 +0.19 (+0.18%)
As of 08/1/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $104.87, which reflects a strong market position and potential for growth.
  • Boston Scientific Co. reported a significant year-over-year revenue increase of 22.8%, indicating robust business performance and demand for its medical devices.
  • The company has a solid return on equity of 19.39%, suggesting effective management and profitability relative to shareholder equity.

Cons of Boston Scientific

  • Insider selling has been notable, with 464,045 shares sold recently, which may raise concerns about the confidence of company executives in the stock's future performance.
  • The stock has experienced a decline of approximately 1.8% recently, which could indicate short-term volatility and market uncertainty.
  • The company has a relatively high P/E ratio of 62.42, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$155.93 billion
P/E Ratio
62.74
Consensus Rating
Buy
Consensus Price Target
$117.50 (+11.5% Upside)
Volume
6.34 million shares
Average Volume
7.77 million shares
Today's Range
$104.06
$106.41
50-Day Range
$98.43
$107.51
52-Week Range
$71.88
$108.94
Dividend Yield
N/A
Stryker stock logo

14. Stryker NYSE:SYK

$378.62 -14.11 (-3.59%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$378.62 0.00 (0.00%)
As of 08/1/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $387, reflecting a strong market position and investor confidence in the company's growth potential.
  • Stryker Co. has a solid earnings report, with earnings per share exceeding expectations, indicating robust financial health and operational efficiency.
  • The company has a high return on equity, showcasing effective management and the ability to generate profits from shareholders' investments.

Cons of Stryker

  • The stock has a relatively high P/E ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent insider selling, including a significant transaction by a director, could raise concerns about the company's future prospects and management confidence.
  • The company's dividend payout ratio is at 45.41%, which, while sustainable, may limit the funds available for reinvestment into growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$144.52 billion
P/E Ratio
50.15
Consensus Rating
Moderate Buy
Consensus Price Target
$429.35 (+13.4% Upside)
Volume
3.01 million shares
Average Volume
1.31 million shares
Today's Range
$372.32
$383.09
50-Day Range
$373.22
$403.34
52-Week Range
$314.93
$406.19
Dividend Yield
0.89%
Danaher stock logo

15. Danaher NYSE:DHR

$197.08 -0.08 (-0.04%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$196.02 -1.06 (-0.54%)
As of 08/1/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. has a strong dividend payout ratio of 27.23%, indicating a commitment to returning value to shareholders through dividends.
  • The current stock price is around $197, which may present a buying opportunity for investors looking for growth potential.
  • Recent analyst ratings show a consensus of "Moderate Buy," with a significant number of analysts assigning buy ratings, suggesting positive market sentiment.

Cons of Danaher

  • Recent price target adjustments by analysts have shown a downward trend, with some targets being lowered significantly, which may indicate concerns about future performance.
  • Insider selling has occurred, with the Chairman selling a substantial number of shares, which could signal a lack of confidence in the company's short-term prospects.
  • The stock has experienced volatility, with a 12-month high of $279.90 and a low of $171.00, suggesting potential instability in its price movements.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$141.12 billion
P/E Ratio
41.93
Consensus Rating
Moderate Buy
Consensus Price Target
$247.61 (+25.6% Upside)
Volume
5.74 million shares
Average Volume
4.66 million shares
Today's Range
$192.26
$197.16
50-Day Range
$184.79
$206.83
52-Week Range
$171.00
$279.90
Dividend Yield
0.65%
Gilead Sciences stock logo

16. Gilead Sciences NASDAQ:GILD

$113.18 +0.89 (+0.79%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$113.07 -0.11 (-0.10%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Recent analyst upgrades have been positive, with multiple firms raising their price targets, indicating strong market confidence in Gilead Sciences, Inc.'s future performance.
  • The current stock price is around $111, which may present a buying opportunity for investors looking to enter at a favorable valuation.
  • Gilead Sciences, Inc. has a consensus rating of "Moderate Buy," suggesting that a majority of analysts believe the stock is a good investment.

Cons of Gilead Sciences

  • Insider selling has been notable, with significant shares sold recently, which may indicate a lack of confidence from those within the company.
  • Despite positive ratings, the average price target remains lower than some recent highs, suggesting potential limitations on short-term price appreciation.
  • Market volatility can impact biopharmaceutical stocks significantly, and Gilead Sciences, Inc. is not immune to broader market fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.79 billion
P/E Ratio
23.83
Consensus Rating
Moderate Buy
Consensus Price Target
$112.36 (-0.7% Downside)
Volume
5.02 million shares
Average Volume
5.54 million shares
Today's Range
$111.85
$113.81
50-Day Range
$105.93
$116.20
52-Week Range
$72.43
$119.96
Dividend Yield
2.79%
Pfizer stock logo

17. Pfizer NYSE:PFE

$23.49 +0.20 (+0.86%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$23.52 +0.03 (+0.11%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $23.27, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has a solid dividend yield of approximately 7.3%, providing a steady income stream for investors.

Cons of Pfizer

  • The company's quarterly revenue has shown a decline of 7.8% year-over-year, raising concerns about its growth trajectory.
  • Analysts have issued a range of ratings, with some indicating a "hold" or "market perform" stance, suggesting uncertainty about future performance.
  • Pfizer's dividend payout ratio is high at 124.64%, which may indicate that the company is paying out more in dividends than it is earning, potentially unsustainable in the long run.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.55 billion
P/E Ratio
17.02
Consensus Rating
Moderate Buy
Consensus Price Target
$28.28 (+20.4% Upside)
Volume
51.29 million shares
Average Volume
40.58 million shares
Today's Range
$23.11
$23.52
50-Day Range
$23.11
$25.77
52-Week Range
$20.92
$31.32
Dividend Yield
7.32%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$462.13 +5.26 (+1.15%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$466.26 +4.13 (+0.89%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $468, which reflects a recent increase of 1.6%, indicating positive market sentiment.
  • Vertex Pharmaceuticals Incorporated has a strong market capitalization of approximately $120.29 billion, suggesting robust financial health and stability.
  • Recent quarterly revenue showed a year-over-year increase of 2.6%, demonstrating the company's ability to grow even in challenging market conditions.

Cons of Vertex Pharmaceuticals

  • The company reported earnings per share (EPS) of $4.06, which missed analysts' expectations, indicating potential challenges in meeting future performance targets.
  • Vertex Pharmaceuticals Incorporated has a negative net margin of 8.91%, suggesting that the company is currently operating at a loss, which could be a concern for profitability.
  • Recent downgrades from analysts, including a shift from "outperform" to "peer perform," may signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.67 billion
P/E Ratio
-117.89
Consensus Rating
Moderate Buy
Consensus Price Target
$509.89 (+10.3% Upside)
Volume
1.86 million shares
Average Volume
1.13 million shares
Today's Range
$453.51
$464.23
50-Day Range
$436.00
$479.53
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$46.75 +1.11 (+2.43%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$46.18 -0.57 (-1.22%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi recently reported earnings per share (EPS) of $0.94, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • The current stock price is around $49.25, which is near its 52-week low, suggesting a potential buying opportunity for investors looking for value.
  • Sanofi has a solid market capitalization of approximately $123.53 billion, reflecting its stability and presence in the healthcare sector.

Cons of Sanofi

  • Sanofi's quarterly revenue was down 11.0% year-over-year, which raises concerns about its growth trajectory and ability to maintain sales levels.
  • The company has a quick ratio of 0.69, which is below 1, indicating potential liquidity issues that could affect its ability to meet short-term obligations.
  • Despite recent upgrades, the overall market sentiment can be volatile, and external factors such as regulatory changes in the healthcare sector could impact Sanofi's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$114.80 billion
P/E Ratio
11.24
Consensus Rating
Buy
Consensus Price Target
$62.00 (+32.6% Upside)
Volume
2.52 million shares
Average Volume
2.25 million shares
Today's Range
$45.97
$46.81
50-Day Range
$45.64
$52.39
52-Week Range
$44.73
$60.12
Dividend Yield
3.42%
Medtronic stock logo

20. Medtronic NYSE:MDT

$89.31 -0.93 (-1.03%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$89.18 -0.14 (-0.15%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $90, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Medtronic plc recently reported strong quarterly earnings, exceeding analysts' expectations with a revenue increase of 3.9% year-over-year, indicating solid business performance.
  • The company has a history of increasing dividends, with a recent quarterly dividend raised to $0.71 per share, reflecting a commitment to returning value to shareholders.

Cons of Medtronic

  • The stock has experienced fluctuations, with a 12-month high of $96.25 and a low of $78.96, indicating potential volatility that could concern risk-averse investors.
  • Despite recent earnings growth, the company's net margin of 13.90% may suggest limited profitability compared to industry peers, which could impact long-term growth potential.
  • Medtronic plc's dividend payout ratio is currently at 78.45%, which may raise concerns about sustainability if earnings do not continue to grow.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$114.54 billion
P/E Ratio
24.67
Consensus Rating
Moderate Buy
Consensus Price Target
$98.19 (+9.9% Upside)
Volume
6.51 million shares
Average Volume
6.82 million shares
Today's Range
$88.69
$89.96
50-Day Range
$80.70
$92.91
52-Week Range
$79.29
$96.25
Dividend Yield
3.18%
Bristol Myers Squibb stock logo

21. Bristol Myers Squibb NYSE:BMY

$44.25 +0.94 (+2.17%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$44.32 +0.08 (+0.17%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $47.63, which is relatively stable compared to its twelve-month high of $63.33, indicating potential for recovery and growth.
  • Recent quarterly earnings showed a significant earnings per share (EPS) of $1.46, surpassing expectations, which reflects strong financial performance and operational efficiency.
  • The company has a robust product pipeline, including treatments for various cancers and other serious conditions, which could drive future revenue growth.

Cons of Bristol Myers Squibb

  • The company has a high debt-to-equity ratio of 2.65, which may indicate financial risk and could affect its ability to invest in growth opportunities.
  • Despite recent revenue growth, the net margin of 11.38% suggests that profitability could be under pressure, which may concern investors looking for strong returns.
  • Analysts predict a modest EPS of 6.74 for the current fiscal year, which may not meet the expectations of aggressive growth investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$90.07 billion
P/E Ratio
17.84
Consensus Rating
Hold
Consensus Price Target
$57.33 (+29.6% Upside)
Volume
18.63 million shares
Average Volume
13.63 million shares
Today's Range
$43.57
$44.46
50-Day Range
$43.37
$50.68
52-Week Range
$42.96
$63.33
Dividend Yield
5.61%
McKesson stock logo

22. McKesson NYSE:MCK

$698.43 +4.89 (+0.71%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$696.85 -1.58 (-0.23%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $720, reflecting a strong market position and investor confidence in the company's future growth.
  • McKesson Co. recently reported earnings that exceeded analyst expectations, indicating robust financial health and operational efficiency.
  • The company has shown significant revenue growth, with an increase of nearly 19% compared to the same quarter last year, suggesting strong demand for its services.

Cons of McKesson

  • The company has a negative return on equity, which may raise concerns about its ability to generate profit from shareholders' equity.
  • Insider selling has been notable, with significant shares sold recently, which could signal a lack of confidence from those within the company.
  • Despite revenue growth, the company did not meet all analyst revenue expectations, which may indicate potential challenges in maintaining growth momentum.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$87.38 billion
P/E Ratio
27.04
Consensus Rating
Moderate Buy
Consensus Price Target
$710.17 (+1.7% Upside)
Volume
960,996 shares
Average Volume
609,203 shares
Today's Range
$688.88
$700.00
50-Day Range
$693.57
$735.41
52-Week Range
$464.42
$737.89
Dividend Yield
0.41%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$356.84 +2.85 (+0.81%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$356.98 +0.15 (+0.04%)
As of 08/1/2025 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $356.84, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • HCA Healthcare, Inc. has a strong market capitalization of approximately $85.84 billion, indicating a solid position in the industry and potential for growth.
  • The company recently announced a quarterly dividend of $0.72 per share, translating to an annualized dividend yield of 0.8%, which can provide a steady income stream for investors.

Cons of HCA Healthcare

  • The company has a relatively high debt-to-equity ratio of 69.07, which may raise concerns about financial leverage and the ability to manage debt effectively.
  • HCA Healthcare, Inc. has a current ratio of 0.98, suggesting that it may struggle to cover short-term liabilities with its current assets, indicating potential liquidity issues.
  • The stock has experienced volatility, with a beta of 1.47, meaning it is more volatile than the market, which could pose risks for conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.84 billion
P/E Ratio
15.00
Consensus Rating
Moderate Buy
Consensus Price Target
$396.46 (+11.1% Upside)
Volume
1.37 million shares
Average Volume
1.63 million shares
Today's Range
$353.39
$358.46
50-Day Range
$334.26
$389.81
52-Week Range
$289.98
$417.14
Dividend Yield
0.81%
CVS Health stock logo

24. CVS Health NYSE:CVS

$62.52 +0.42 (+0.68%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$62.50 -0.02 (-0.03%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. reported earnings per share of $1.81 for the latest quarter, significantly exceeding analysts' expectations, indicating strong financial performance.
  • The company has a solid return on equity of 10.59%, which suggests effective management and profitability relative to shareholder equity.
  • CVS Health Co. recently announced a quarterly dividend of $0.665, translating to an annualized dividend yield of approximately 4.26%, providing a steady income stream for investors.

Cons of CVS Health

  • The company has a net margin of only 1.39%, which may raise concerns about profitability and operational efficiency compared to competitors.
  • CVS Health Co. has faced recent downgrades from analysts, with UBS Group lowering their target price from $71.00 to $67.00, indicating a cautious outlook.
  • Despite a strong earnings report, the company’s revenue growth of 8.4% may not be sufficient to meet the high expectations set by the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.30 billion
P/E Ratio
17.46
Consensus Rating
Moderate Buy
Consensus Price Target
$75.39 (+20.6% Upside)
Volume
11.38 million shares
Average Volume
9.08 million shares
Today's Range
$61.19
$62.70
50-Day Range
$58.82
$69.56
52-Week Range
$43.56
$72.51
Dividend Yield
4.26%
GSK stock logo

25. GSK NYSE:GSK

$37.53 +0.38 (+1.02%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$37.45 -0.08 (-0.21%)
As of 08/1/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $38, which is relatively stable compared to its 52-week high of $44.67, indicating potential for recovery and growth.
  • GSK plc recently reported earnings that exceeded analysts' expectations, showcasing strong financial performance with a revenue increase compared to the previous year.
  • The company has a solid dividend yield of approximately 4.43%, providing a steady income stream for investors.

Cons of GSK

  • Analysts have issued a "strong sell" rating, indicating concerns about the stock's future performance and potential risks.
  • The company's debt-to-equity ratio is relatively high, which may raise concerns about financial leverage and risk management.
  • Despite recent earnings growth, the net margin remains modest, suggesting that profitability could be a concern in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.57 billion
P/E Ratio
17.38
Consensus Rating
Hold
Consensus Price Target
$37.38 (-0.4% Downside)
Volume
3.68 million shares
Average Volume
6.29 million shares
Today's Range
$37.18
$37.79
50-Day Range
$36.21
$42.50
52-Week Range
$31.72
$44.67
Dividend Yield
4.55%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$262.26 -5.12 (-1.91%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$262.16 -0.10 (-0.04%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group recently reported strong quarterly earnings, with earnings per share exceeding expectations, indicating robust financial performance.
  • The current stock price is around $262, which may present a buying opportunity for investors looking for value in a well-rated company.
  • Analysts have given The Cigna Group a consensus rating of "Moderate Buy," suggesting positive sentiment and potential for price appreciation.

Cons of Cigna Group

  • The stock has experienced a decline of approximately 1.9% recently, which may raise concerns about short-term volatility.
  • Despite positive earnings, the company's net margin of 1.92% suggests that profitability could be under pressure, which may affect future earnings.
  • With a debt-to-equity ratio of 0.65, The Cigna Group has a moderate level of debt, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$70.01 billion
P/E Ratio
14.32
Consensus Rating
Buy
Consensus Price Target
$378.67 (+44.4% Upside)
Volume
3.43 million shares
Average Volume
1.81 million shares
Today's Range
$256.89
$271.00
50-Day Range
$262.26
$334.71
52-Week Range
$256.89
$370.83
Dividend Yield
2.30%
Zoetis stock logo

27. Zoetis NYSE:ZTS

$147.40 +1.61 (+1.10%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$147.36 -0.03 (-0.02%)
As of 08/1/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $147.40, which reflects a stable market position and potential for growth.
  • Zoetis Inc. reported a strong quarterly earnings performance, with earnings per share exceeding analysts' expectations, indicating robust financial health.
  • The company has a high net margin, showcasing its efficiency in converting revenue into profit, which is attractive for investors seeking profitability.

Cons of Zoetis

  • Recent target price reductions by analysts, including a downgrade to a "neutral" rating, may indicate concerns about future performance.
  • The stock has experienced fluctuations, with a 1-year high of $200.33 and a low of $139.70, suggesting volatility that could deter risk-averse investors.
  • Insider selling activity, such as the recent sale of shares by an executive vice president, may raise questions about the company's future outlook from those within the organization.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$65.62 billion
P/E Ratio
26.46
Consensus Rating
Moderate Buy
Consensus Price Target
$204.63 (+38.8% Upside)
Volume
3.15 million shares
Average Volume
3.31 million shares
Today's Range
$145.10
$147.79
50-Day Range
$145.76
$170.40
52-Week Range
$139.70
$200.33
Dividend Yield
1.36%
Elevance Health stock logo

28. Elevance Health NYSE:ELV

$274.10 -8.98 (-3.17%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$274.54 +0.44 (+0.16%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$61.72 billion
P/E Ratio
11.66
Consensus Rating
Moderate Buy
Consensus Price Target
$418.19 (+52.6% Upside)
Volume
3.38 million shares
Average Volume
3.20 million shares
Today's Range
$273.84
$288.09
50-Day Range
$274.10
$395.76
52-Week Range
$273.84
$567.26
Dividend Yield
2.49%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$558.87 +13.41 (+2.46%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$564.00 +5.13 (+0.92%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Market Capitalization
$60.34 billion
P/E Ratio
14.08
Consensus Rating
Moderate Buy
Consensus Price Target
$828.86 (+48.3% Upside)
Volume
1.66 million shares
Average Volume
941,817 shares
Today's Range
$542.89
$583.28
50-Day Range
$483.07
$605.39
52-Week Range
$476.49
$1,211.20
Dividend Yield
0.63%
Cencora stock logo

30. Cencora NYSE:COR

$288.31 +2.23 (+0.78%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$288.70 +0.38 (+0.13%)
As of 08/1/2025 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $290, which is near its 12-month high of $309.35, indicating strong market performance.
  • The company reported a significant increase in earnings per share, achieving $4.42, which surpassed analysts' expectations, showcasing robust financial health.
  • Cencora, Inc. has demonstrated a year-over-year revenue growth of over 10%, reflecting its expanding market presence and operational efficiency.

Cons of Cencora

  • The company has a high debt-to-equity ratio of 6.01, suggesting that it relies heavily on debt financing, which could pose risks in economic downturns.
  • Insider selling has been notable, with over 34,000 shares sold recently, which may indicate a lack of confidence among those closest to the company.
  • The stock has experienced fluctuations, with a recent trading volume significantly lower than its average, which could signal reduced investor interest.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.88 billion
P/E Ratio
33.45
Consensus Rating
Moderate Buy
Consensus Price Target
$309.83 (+7.5% Upside)
Volume
1.14 million shares
Average Volume
998,714 shares
Today's Range
$285.02
$290.08
50-Day Range
$283.94
$302.43
52-Week Range
$218.65
$309.35
Dividend Yield
0.76%
Alnylam Pharmaceuticals stock logo

31. Alnylam Pharmaceuticals NASDAQ:ALNY

$401.80 +9.56 (+2.44%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$394.62 -7.18 (-1.79%)
As of 08/1/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $401.80, reflecting a strong market interest and potential for growth.
  • Alnylam Pharmaceuticals, Inc. reported a revenue increase of over 20% year-over-year, indicating strong business performance and demand for its products.
  • Institutional investors own approximately 92.97% of the company's stock, suggesting strong confidence from major financial players in the market.

Cons of Alnylam Pharmaceuticals

  • The company has a high debt-to-equity ratio of 8.88, which may raise concerns about financial leverage and the ability to manage debt effectively.
  • Alnylam Pharmaceuticals, Inc. reported a negative return on equity of over 510%, indicating that the company is not currently generating profits relative to shareholder equity.
  • The stock has a P/E ratio that is negative, which can be a red flag for investors looking for profitability and growth potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.67 billion
P/E Ratio
-162.67
Consensus Rating
Moderate Buy
Consensus Price Target
$392.13 (-2.4% Downside)
Volume
1.78 million shares
Average Volume
1.12 million shares
Today's Range
$382.19
$401.80
50-Day Range
$285.56
$401.80
52-Week Range
$205.87
$402.43
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

32. Becton, Dickinson and Company NYSE:BDX

$176.19 -2.06 (-1.16%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$180.14 +3.96 (+2.24%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company recently reported earnings per share of $3.35, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Becton, Dickinson and Company has shown a year-over-year revenue increase of 4.5%, suggesting a positive trend in sales and market demand for its medical products.
  • The current stock price is around $250, which is within a range that reflects the company's stability and growth potential in the medical instruments sector.

Cons of Becton, Dickinson and Company

  • The company’s revenue for the latest quarter fell short of analyst expectations, which may raise concerns about future growth and market competitiveness.
  • With a dividend payout ratio of 79.39%, there may be limited room for future dividend increases, which could affect income-focused investors.
  • The stock has a 12-month high of $251.99, indicating that it may be nearing its peak, which could limit upside potential for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.50 billion
P/E Ratio
33.62
Consensus Rating
Hold
Consensus Price Target
$212.88 (+20.8% Upside)
Volume
4.69 million shares
Average Volume
3.05 million shares
Today's Range
$174.49
$177.45
50-Day Range
$168.54
$185.52
52-Week Range
$163.33
$251.99
Dividend Yield
2.36%
Edwards Lifesciences stock logo

33. Edwards Lifesciences NYSE:EW

$79.30 -0.01 (-0.01%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$79.39 +0.09 (+0.11%)
As of 08/1/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $80.29, which reflects a potential upside based on recent analyst price targets.
  • Multiple brokerages have recently raised their price targets for Edwards Lifesciences Co., indicating positive market sentiment and potential for growth.
  • The company has a strong market capitalization of approximately $47.10 billion, suggesting stability and investor confidence.

Cons of Edwards Lifesciences

  • Despite recent price target increases, the stock has shown volatility, which may pose risks for investors seeking stable returns.
  • The company has a relatively high P/E ratio, which could indicate that the stock is overvalued compared to its earnings.
  • There is a mix of ratings from analysts, with some holding a sell rating, which may create uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.52 billion
P/E Ratio
11.41
Consensus Rating
Moderate Buy
Consensus Price Target
$85.71 (+8.1% Upside)
Volume
3.15 million shares
Average Volume
5.06 million shares
Today's Range
$77.96
$79.73
50-Day Range
$73.31
$81.15
52-Week Range
$59.41
$83.00
Dividend Yield
N/A
Veeva Systems stock logo

34. Veeva Systems NYSE:VEEV

$281.05 -3.15 (-1.11%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$279.90 -1.15 (-0.41%)
As of 08/1/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $285, which reflects a strong market position and investor confidence in the company's growth potential.
  • Veeva Systems Inc. has a solid reputation for providing cloud-based software solutions tailored for the life sciences industry, which is a growing market with increasing demand for innovative technology.
  • Recent insider trading activity indicates that company executives are actively managing their positions, which can be a sign of confidence in the company's future performance.

Cons of Veeva Systems

  • Recent insider sales, including a senior vice president reducing their position by 8.35%, may raise concerns about the company's short-term outlook.
  • Insider trading activity has shown that a total of 1,378 shares were sold in the last ninety days, which could indicate a lack of confidence among some insiders.
  • The stock has experienced fluctuations, and while it remains strong, any significant downturn could impact investor sentiment negatively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.93 billion
P/E Ratio
59.54
Consensus Rating
Moderate Buy
Consensus Price Target
$274.17 (-2.4% Downside)
Volume
996,717 shares
Average Volume
1.30 million shares
Today's Range
$278.00
$283.53
50-Day Range
$233.41
$292.77
52-Week Range
$177.41
$296.72
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

35. Takeda Pharmaceutical NYSE:TAK

$14.17 +0.45 (+3.28%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$14.13 -0.04 (-0.28%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is approximately $14.67, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has recently experienced a significant increase in trading volume, indicating heightened investor interest and potential momentum.
  • The company reported a market capitalization of around $46.68 billion, suggesting a strong position in the market and potential for growth.

Cons of Takeda Pharmaceutical

  • The company recently reported earnings per share (EPS) of $0.16, which missed the consensus estimate, indicating potential challenges in meeting financial expectations.
  • Takeda Pharmaceutical Company Limited's revenue for the last quarter was below analyst estimates, which may raise concerns about its growth trajectory.
  • The stock has shown volatility, with fluctuations in trading volume and price, which could pose risks for investors seeking stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.09 billion
P/E Ratio
47.23
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
6.22 million shares
Average Volume
5.03 million shares
Today's Range
$14.07
$14.23
50-Day Range
$13.60
$15.55
52-Week Range
$12.80
$15.53
Dividend Yield
3.90%
Haleon stock logo

36. Haleon NYSE:HLN

$9.67 +0.24 (+2.55%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$9.68 +0.01 (+0.05%)
As of 08/1/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Recent upgrades from major financial institutions, including Morgan Stanley and BNP Paribas, indicate strong confidence in Haleon plc's growth potential, with price targets set at $11.25 and $13.40 respectively.
  • The current stock price is around $9.65, which may present a buying opportunity for investors looking for undervalued stocks in the consumer healthcare sector.
  • Haleon plc has a solid market capitalization of approximately $43.35 billion, suggesting a stable financial foundation and the ability to invest in growth initiatives.

Cons of Haleon

  • Despite recent upgrades, the stock has experienced a decline of about 1.6%, which may raise concerns about short-term performance and market sentiment.
  • The company has a relatively high P/E ratio of 24.74, which could indicate that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
  • Haleon plc's debt-to-equity ratio of 0.53 suggests a moderate level of debt, which could pose risks if the company faces financial challenges or rising interest rates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.44 billion
P/E Ratio
24.80
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+27.5% Upside)
Volume
16.93 million shares
Average Volume
12.37 million shares
Today's Range
$9.62
$9.76
50-Day Range
$9.42
$11.42
52-Week Range
$8.86
$11.42
Dividend Yield
2.58%
Alcon stock logo

37. Alcon NYSE:ALC

$87.85 +0.30 (+0.34%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$87.95 +0.10 (+0.11%)
As of 08/1/2025 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that could attract investors.
  • Institutional ownership is significant, with a high percentage indicating confidence from large investors.

Cons of Alcon

  • Despite recent performance, the average daily volume has decreased, which may indicate reduced trading interest.
  • The month-to-month change in shares shorted has shown fluctuations, which could signal uncertainty in the stock's future.
  • While institutional ownership is high, it remains below 75%, suggesting that there is still room for skepticism among larger investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.33 billion
P/E Ratio
39.04
Consensus Rating
Moderate Buy
Consensus Price Target
$106.13 (+20.8% Upside)
Volume
945,061 shares
Average Volume
1.52 million shares
Today's Range
$86.20
$87.92
50-Day Range
$84.77
$92.25
52-Week Range
$80.48
$101.10
Dividend Yield
N/A
IDEXX Laboratories stock logo

38. IDEXX Laboratories NASDAQ:IDXX

$535.54 +1.23 (+0.23%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$535.86 +0.33 (+0.06%)
As of 08/1/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $535, reflecting a strong market position and investor confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. has seen significant increases in institutional investments, indicating strong confidence from major investors.
  • The company has a solid financial foundation, with a low debt-to-equity ratio, suggesting it is well-positioned to manage its liabilities effectively.

Cons of IDEXX Laboratories

  • The stock has a high price-to-earnings (P/E) ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling activity has been noted, with a director recently selling a significant number of shares, which could raise concerns about the company's future prospects.
  • Despite strong institutional support, the high concentration of ownership by institutional investors (over 87%) may lead to volatility if these investors decide to sell.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.07 billion
P/E Ratio
49.50
Consensus Rating
Moderate Buy
Consensus Price Target
$557.88 (+4.2% Upside)
Volume
760,497 shares
Average Volume
556,641 shares
Today's Range
$527.81
$539.11
50-Day Range
$501.57
$573.07
52-Week Range
$356.14
$579.47
Dividend Yield
N/A
argenex stock logo

39. argenex NASDAQ:ARGX

$673.80 +3.47 (+0.52%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$673.88 +0.09 (+0.01%)
As of 08/1/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The company reported strong earnings per share of $2.58, surpassing analysts' expectations, indicating robust financial performance.
  • With a return on equity of 16.15%, argenx SE demonstrates effective management of shareholder equity, which can be appealing to investors.
  • The current stock price is around $720, reflecting positive market sentiment and potential for growth.

Cons of argenex

  • Despite strong earnings, the stock price has shown volatility, which may concern risk-averse investors.
  • There is a high level of competition in the biotechnology sector, which could impact argenx SE's market share and profitability.
  • Analysts have varying price targets, with some as high as $1,100, indicating uncertainty in future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.24 billion
P/E Ratio
34.55
Consensus Rating
Buy
Consensus Price Target
$736.81 (+9.4% Upside)
Volume
633,642 shares
Average Volume
446,291 shares
Today's Range
$661.08
$680.91
50-Day Range
$537.92
$673.80
52-Week Range
$475.65
$689.13
Dividend Yield
N/A
ResMed stock logo

40. ResMed NYSE:RMD

$278.78 +6.84 (+2.52%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$279.15 +0.37 (+0.13%)
As of 08/1/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $277, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • ResMed Inc. has a strong market capitalization of approximately $40.64 billion, suggesting a solid position in the healthcare sector.
  • Recent analyst upgrades, including a price target increase to $290 from JPMorgan Chase & Co., indicate growing confidence in the company's future performance.

Cons of ResMed

  • Insider selling has been notable, with recent transactions indicating a decrease in ownership by key executives, which may raise concerns about their confidence in the company's future.
  • Despite recent upgrades, some analysts have issued hold ratings, suggesting that not all market participants are convinced of the stock's potential for significant growth.
  • The company's stock has experienced fluctuations, with a twelve-month low of around $199.92, indicating potential volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.88 billion
P/E Ratio
29.31
Consensus Rating
Moderate Buy
Consensus Price Target
$274.83 (-1.4% Downside)
Volume
1.80 million shares
Average Volume
1.03 million shares
Today's Range
$271.11
$281.90
50-Day Range
$243.03
$278.78
52-Week Range
$199.92
$281.90
Dividend Yield
0.76%
Cardinal Health stock logo

41. Cardinal Health NYSE:CAH

$155.97 +0.75 (+0.48%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$156.22 +0.25 (+0.16%)
As of 08/1/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $157.86, which reflects a positive trend in the market and could indicate potential for growth.
  • Recent upgrades from analysts, including a "strong-buy" rating from Wall Street Zen, suggest strong confidence in the company's future performance.
  • Cardinal Health, Inc. has consistently reported earnings that exceed analyst expectations, indicating strong operational performance and effective management.

Cons of Cardinal Health

  • The company has a negative return on equity, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Despite recent revenue growth, the company reported a net margin of only 0.70%, indicating that profit generation is relatively low compared to its sales.
  • Analysts have mixed ratings, with three holding a neutral stance, which may suggest uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.23 billion
P/E Ratio
24.33
Consensus Rating
Moderate Buy
Consensus Price Target
$158.07 (+1.3% Upside)
Volume
1.59 million shares
Average Volume
1.71 million shares
Today's Range
$153.27
$157.41
50-Day Range
$152.73
$167.92
52-Week Range
$96.05
$168.44
Dividend Yield
1.31%
BeOne Medicines stock logo

42. BeOne Medicines NASDAQ:ONC

$299.01 -2.12 (-0.70%)
As of 08/1/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$32.77 billion
P/E Ratio
-80.38
Consensus Rating
Buy
Consensus Price Target
$327.56 (+9.5% Upside)
Volume
543,060 shares
Average Volume
430,030 shares
Today's Range
$288.07
$299.29
50-Day Range
$238.31
$305.74
52-Week Range
$155.75
$308.87
Dividend Yield
N/A
Agilent Technologies stock logo

43. Agilent Technologies NYSE:A

$113.51 -1.30 (-1.13%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$113.50 -0.01 (0.00%)
As of 08/1/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The company recently reported earnings per share of $1.31, exceeding expectations, which indicates strong financial performance and potential for growth.
  • Agilent Technologies, Inc. has shown a year-over-year revenue increase of 6.0%, suggesting a positive trend in sales and market demand.
  • The current stock price is around $117, reflecting a stable valuation in the market, which may attract investors looking for solid investment opportunities.

Cons of Agilent Technologies

  • Analysts have mixed ratings on the stock, with some reducing their price targets, indicating uncertainty about future performance.
  • The dividend payout ratio is 24.44%, which, while sustainable, may limit the company's ability to reinvest profits into growth opportunities.
  • Recent insider selling by the CEO could signal a lack of confidence in the stock's short-term performance, which may concern potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.24 billion
P/E Ratio
28.03
Consensus Rating
Moderate Buy
Consensus Price Target
$139.77 (+23.1% Upside)
Volume
1.89 million shares
Average Volume
1.88 million shares
Today's Range
$111.19
$114.32
50-Day Range
$108.61
$124.18
52-Week Range
$96.43
$153.84
Dividend Yield
0.87%
GE HealthCare Technologies stock logo

44. GE HealthCare Technologies NASDAQ:GEHC

$69.85 -1.47 (-2.06%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$70.10 +0.25 (+0.36%)
As of 08/1/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported strong earnings, with earnings per share (EPS) of $1.06, surpassing expectations, indicating robust financial health and operational efficiency.
  • GE HealthCare Technologies Inc. has announced a significant share buyback plan of $1.00 billion, which suggests that the leadership believes the stock is undervalued, potentially enhancing shareholder value.
  • The current stock price is around $89, reflecting a solid market position and investor confidence in the company's growth prospects.

Cons of GE HealthCare Technologies

  • The stock has experienced fluctuations, with a one-year high of $94.80 and a low of $57.65, indicating potential volatility that could deter risk-averse investors.
  • Despite recent growth, the company has a relatively low dividend yield of 0.18%, which may not be attractive for income-focused investors.
  • The price-to-earnings (P/E) ratio of 15.09 suggests that the stock may be fairly valued, limiting potential upside for investors seeking high-growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.89 billion
P/E Ratio
14.31
Consensus Rating
Moderate Buy
Consensus Price Target
$88.55 (+26.8% Upside)
Volume
5.05 million shares
Average Volume
4.21 million shares
Today's Range
$69.09
$70.90
50-Day Range
$69.16
$77.74
52-Week Range
$57.65
$94.80
Dividend Yield
0.20%
DexCom stock logo

45. DexCom NASDAQ:DXCM

$79.28 -1.49 (-1.84%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$79.74 +0.47 (+0.59%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $88, reflecting a strong market position in the medical device sector, particularly in continuous glucose monitoring systems.
  • Recent institutional investments indicate growing confidence in DexCom, Inc., with several hedge funds increasing their holdings significantly, suggesting potential for future growth.
  • DexCom, Inc. specializes in innovative medical technology, focusing on continuous glucose monitoring systems, which are essential for diabetes management, a growing health concern globally.

Cons of DexCom

  • Insider selling has occurred recently, with a total of 28,656 shares sold, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The executive vice president's recent sale of shares, resulting in a decrease in their position, could signal potential issues or a lack of confidence in the company's immediate future.
  • Despite the strong institutional backing, the low insider ownership percentage might indicate a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.09 billion
P/E Ratio
55.06
Consensus Rating
Moderate Buy
Consensus Price Target
$99.89 (+26.0% Upside)
Volume
5.24 million shares
Average Volume
3.22 million shares
Today's Range
$78.93
$80.86
50-Day Range
$79.28
$89.53
52-Week Range
$57.52
$93.25
Dividend Yield
N/A
IQVIA stock logo

46. IQVIA NYSE:IQV

$182.44 -3.42 (-1.84%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$186.25 +3.81 (+2.09%)
As of 08/1/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The stock has received multiple buy ratings from analysts, indicating strong confidence in its future performance.
  • Recent price targets from analysts suggest significant upside potential, with an average target around $228.62.
  • IQVIA Holdings Inc. has shown substantial growth in institutional ownership, with hedge funds owning over 89% of the stock, reflecting strong investor interest.

Cons of IQVIA

  • The stock has experienced volatility, with recent trading showing fluctuations that could concern risk-averse investors.
  • Some analysts have downgraded their ratings, indicating potential caution regarding the stock's future performance.
  • The company has a relatively high debt-to-equity ratio of 2.45, which may raise concerns about financial stability and leverage.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.01 billion
P/E Ratio
26.40
Consensus Rating
Moderate Buy
Consensus Price Target
$228.62 (+25.3% Upside)
Volume
1.64 million shares
Average Volume
2.40 million shares
Today's Range
$178.92
$184.00
50-Day Range
$136.96
$201.06
52-Week Range
$134.65
$252.88
Dividend Yield
N/A
Humana stock logo

47. Humana NYSE:HUM

$247.19 -2.68 (-1.07%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$247.28 +0.09 (+0.03%)
As of 08/1/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $251.55, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Humana Inc. has shown strong financial performance, with a recent earnings report indicating a significant increase in earnings per share, surpassing analyst expectations.
  • Institutional investors hold a substantial 92.38% of the company's stock, indicating strong confidence in Humana Inc.'s future prospects.

Cons of Humana

  • Analysts have set varying price targets, with some reducing their expectations, which may indicate uncertainty about the stock's future performance.
  • The stock has experienced volatility, with a 52-week high of $382.72 and a low of $206.87, suggesting potential risks for investors.
  • Humana Inc. operates in a highly competitive market, which could impact its market share and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.73 billion
P/E Ratio
18.97
Consensus Rating
Hold
Consensus Price Target
$281.62 (+13.9% Upside)
Volume
1.76 million shares
Average Volume
1.94 million shares
Today's Range
$244.83
$252.00
50-Day Range
$220.08
$264.97
52-Week Range
$206.87
$382.72
Dividend Yield
1.43%
BioNTech stock logo

48. BioNTech NASDAQ:BNTX

$107.34 -0.16 (-0.15%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$107.38 +0.03 (+0.03%)
As of 08/1/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • The current stock price is around $112.89, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Recent coverage by analysts has resulted in multiple buy ratings, indicating strong market confidence in BioNTech SE's future performance.
  • BioNTech SE has a robust market capitalization of approximately $27.14 billion, suggesting a solid financial foundation and potential for further growth.

Cons of BioNTech

  • The company has a negative price-to-earnings (PE) ratio, which may indicate challenges in profitability and could deter risk-averse investors.
  • Despite recent positive ratings, the stock has shown volatility, with a beta of 1.29, suggesting it may be more susceptible to market fluctuations.
  • BioNTech SE's stock has a wide range in its 52-week performance, with a low of $76.53 and a high of $131.49, indicating potential instability in its market value.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.80 billion
P/E Ratio
-31.57
Consensus Rating
Moderate Buy
Consensus Price Target
$136.58 (+27.2% Upside)
Volume
840,683 shares
Average Volume
640,501 shares
Today's Range
$104.64
$107.48
50-Day Range
$95.71
$115.64
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
Koninklijke Philips stock logo

49. Koninklijke Philips NYSE:PHG

$26.46 +0.26 (+0.99%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$26.18 -0.28 (-1.04%)
As of 08/1/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $26.46, which reflects a recent upward trend, indicating potential for growth.
  • Recent quarterly earnings exceeded expectations, with earnings per share reported at $0.41, surpassing the consensus estimate, showcasing strong financial performance.
  • Institutional investors hold a significant portion of the stock, with 13.67% ownership, suggesting confidence in the company's future prospects.

Cons of Koninklijke Philips

  • The company has a high price-to-earnings (P/E) ratio of 139.26, which may indicate that the stock is overvalued compared to its earnings, posing a risk for potential investors.
  • Despite recent revenue growth, the net margin is relatively low at 1.00%, which could raise concerns about profitability and operational efficiency.
  • Market volatility is a concern, as indicated by the stock's beta of 0.76, suggesting that the stock may not be as stable as some investors prefer.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.48 billion
P/E Ratio
139.26
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
1.78 million shares
Average Volume
1.30 million shares
Today's Range
$26.25
$26.69
50-Day Range
$22.08
$28.02
52-Week Range
$21.48
$32.91
Dividend Yield
3.11%
Mettler-Toledo International stock logo

50. Mettler-Toledo International NYSE:MTD

$1,198.77 -34.91 (-2.83%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$1,197.94 -0.83 (-0.07%)
As of 08/1/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,159, which reflects a strong market position and investor confidence in the company's growth potential.
  • The company reported earnings per share (EPS) of $8.19 for the latest quarter, exceeding analysts' expectations, indicating robust financial performance.
  • Mettler-Toledo International Inc. has a market capitalization of approximately $26.31 billion, suggesting it is a well-established player in the medical instruments sector.

Cons of Mettler-Toledo International

  • The company experienced a 4.6% decline in revenue compared to the same quarter last year, which may raise concerns about future growth prospects.
  • Mettler-Toledo International Inc. has a negative return on equity of 556.22%, indicating that the company is not generating profit from its equity, which could deter potential investors.
  • Insider ownership is relatively low at 0.77%, which may suggest a lack of confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.91 billion
P/E Ratio
30.36
Consensus Rating
Hold
Consensus Price Target
$1,298.50 (+8.3% Upside)
Volume
339,593 shares
Average Volume
172,271 shares
Today's Range
$1,135.53
$1,233.68
50-Day Range
$1,115.43
$1,266.11
52-Week Range
$946.69
$1,521.01
Dividend Yield
N/A